Research and development projects

Examples of actions taken by scientific teams in Poland

Area of research and developmentInstitutionResearch results and publications
PHIRI is a roll-out of the research infrastructure on population health information to facilitate and generate the best available evidence for research on health and well-being of populations as impacted by COVID-19.Ministry of Health, Department of Analysis and Strategyproject summary
Polymeric inhibitors (chitosan derivatives) of SARS-CoV-2 and MERS-CoV infection targeting viral S protein. Studies on the mechanisms of the viral entry into cells.Laboratory of Virology, Malopolska Center of Biotechnology of the Jagiellonian University in KrakowHTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV (preprint)
Studies on the relationship between human gene polymorphisms of ACE2 and TMPRSS2, which are involved in SARS-CoV-2 infection and their possible impact on the clinical outcome of COVID-19.Institute of Bioorganic Chemistry, Polish Academy of Sciences in Poznanproject summary
Biochemical characterisation of the main protease of SARS-CoV-2.Department of Chemical Biology and Bioimaging, Wroclaw University of Science and TechnologySubstrate specificity profiling of SARS-CoV-2 main protease enables design of activity-based probes for patient-sample imaging (preprint)
Computer-aided synthesis design for efficient synthesis of compounds used in COVID-19 therapyInstitute of Organic Chemistry, Polish Academy of Sciences in WarsawComputer-Assisted Planning of Hydroxychloroquine’s Syntheses Commencing from Inexpensive Substrates and Bypassing Patented Routes (preprint)
Structural research on SARS-CoV-2 proteins for the development of new antiviral drugs.International Institute of Molecular and Cell Biology in Warsaw

Funding opportunities - who and how can get support?

In order to raise funds for COVID-19 research, scientific teams can apply for support and funding through various national competitions supporting a wide range of R&D projects. Within the COVID-HUB-PL platform it is possible to support new projects through consistent access to various data sources, use of the ICT infrastructure of science and dedicated services and analytical tools developed to fight the COVID-19 pandemic in Poland, Europe and worldwide.

Implementation of R&D results in Poland

Planned further scientific research on SARS-CoV-2 genetic variability and identification of biomarkers and risk factors in the course of COVID-19 in order to create a model of the SARS-CoV-2 pandemic in Poland in cooperation with various scientific entities around the common research data space shared and shared on the COVID-HUB-PL platform.


Logotyp projektu Regional Covid-HUB Wielkopolska      

As part of the REGIONAL COVID-HUB project, it is planned to use NGS data generated at IBCH PAS concerning samples from Wielkopolska region to create (i) a virtual model of the SARS-CoV-2 pandemic in the voivodeship and (ii) determine the impact of COVID-19 on the course of intra-individual variability of SARS-CoV-2. In addition, using the biological material collected at IBCH PAN, additional sequencing will be carried out targeting the pathogens of the respiratory system co-occurring with SARS-CoV-2, including other coronaviruses. RNA sequencing of selected COVID-19 patients' samples will also be performed, which will allow to determine genetic polymorphism and expression levels of selected genes encoding proteins potentially involved in SARS-CoV-2 penetration into cells and proteins involved in the immune response.

The research and development scheme proposed in the project assumes carrying out a series of specialized analyses using high-throughput research methods that require significant computing power. SARS-CoV-2 genomic sequences will be subjected to phylogenetic analysis by comparing all known SARS-CoV-2 sequences in Poland, Europe and the world. The data processed in this way, together with information about the time of diagnosis and the place of origin of the infected person, will be visualized as an interactive map of the SARS-CoV-2 pandemic in Wielkopolska region.

Data characterising coexisting respiratory pathogens will be mapped to the reference genome database of such pathogens. The result obtained will be both qualitative and quantitative. The accompanying NGS data generated for human RNA will be used to quantify the expression of genes related to infection and immune response. Additional metadata describing the place of origin of the infected person, time of diagnosis and the course of COVID-19 will be obtained from the National Register of Patients with COVID-19.

We assume that all available data will be used in the scope regulated by the Regulation of the Minister of Health of April 7, 2020 on National Register of Patients with COVID-19 (Journal of Laws of 2020, item 625). Based on the obtained data set, we will analyse the association between the measured parameters and the course of COVID-19.